Axelios 1 by Roche: status and timeline

Milestones

Next · FDA submission for clinical diagnostics

Axelios 1 platform announced and launched for research use29 Jun 2026Complete.
FDA submission for clinical diagnosticsTarget 2026Not yet reached.
FDA approval for clinical useTarget 2027Not yet reached.

Most important updates

Roche launches Axelios 1 sequencing platform with same-day whole-genome capability29 Jun 2026

Upcoming

2026FDA submission for clinical diagnostics (next)
2027FDA approval for clinical use

Current obstacles

Market adoption against incumbentIllumina has >90% market share in genomic sequencing; Roche must overcome switching costs and established customer relationships.
Clinical regulatory pathwayFDA approval for diagnostic use is pending; clinical acceptance will depend on head-to-head validation against Illumina platforms.

Physics limits

Nanopore accuracy trade-offWhile accurate, nanopore sequencing typically requires more computational correction than short-read systems, which adds post-processing cost and latency.
Read length versus densityLonger reads are easier to analyze but come at the cost of lower throughput per run compared to short-read systems like Illumina.

How it works

3 parts

Expansion

Xpandomer chemistry

DNA/RNA expanded 50x to larger polymers, easier to detect reliably.

Detection

Reusable nanopore array

Millions of CMOS nanopores read Xpandomers in parallel, real-time base calling.

Scalability

Flexible run sizes

Single instrument, same workflow for small or large batches; results same day.

Spec sheet

Spec	Axelios 1
Maximum read length	~1500 bp^R (reported)
Sample to variant result	Same day^R (reported)
Axelios 1 list price	$750,000 USD^R (reported)

^R reported by the company

Papers & demos

1 item

Jun 2026demo
Axelios 1 platform launched with same-day whole genome sequencing (opens roche.com)Roche's most significant sequencing platform launch, based on proprietary SBX technology developed over years of R&D.

Update log

1 update

Mon 29 Jun

Major: Roche launches Axelios 1 sequencing platform with same-day whole-genome capabilityPressHardware

About Roche

The team behind Axelios 1

Roche

Diagnostics, pharmaceuticals, obesity, sequencing

Swiss pharma giant (Basel, 1896) developing obesity drugs and sequencing systems. Acquired Carmot Therapeutics (2024) and partnered with Zealand Pharma for obesity treatments. Launched Axelios 1 (June 2026), a next-gen sequencing platform with same-day whole-genome analysis.

Obesity portfolio: CT-388 (once-weekly), CT-996 (daily oral), and petrelintide combo (Phase 3 by 2026).
Axelios 1 (June 2026): same-day whole genomes via SBX chemistry; first pharma sequencer vs Illumina.
SIX-listed, ~112,000 employees, established diagnostics and medicines across pharma.

roche.com (opens roche.com)Company profile →

Founded: 1896130 yrs
Headquarters: Switzerland
Status: Public
Valuation: public
Staff: ~112,000
Works in: BiotechGenomics & sequencing
Coverage: 2 programs · 4 updateslatest 29 Jun 2026checked 10 Oct
Partners: Zealand Pharma (opens zealandpharma.com)10x Genomics (opens 10xgenomics.com)
People: Thomas Schinecker (opens roche.com)Chief Executive Officer

Spec

Axelios 1

Maximum read length

~1500 bp^R (reported)

Sample to variant result

Same day^R (reported)

Axelios 1 list price

$750,000 USD^R (reported)